OR WAIT null SECS
March 08, 2019
Procarta Biosystems has received investment from Novo Holdings REPAIR Impact Fund to the tune of €1.5 million, which will be used to develop a new class of antibiotics to tackle AMR.
OSE Immunotherapeutics has been granted authorization to commence a Phase I clinical trial for checkpoint inhibitor BI 765063 (previously OSE-172).
March 05, 2019
The acquisition will establish a clinical pipeline for Biogen of gene-therapy candidates in ophthalmology.
March 01, 2019
The technology uses a silica nanoparticle to deliver vaccines and cancer treatments.
The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac partner to develop a transportable mRNA vaccine manufacturing platform.
February 27, 2019
The $4.3-billion acquisition is expected to strengthen Roche’s gene therapy pipeline.
February 22, 2019
Valitacell and Solentim, have announced a collaboration aimed at the acceleration of discovery and development of biologic drugs and advanced cell therapies.
A multi-partner collaboration has been announced, which will target the acceleration of the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cell lines.
February 21, 2019
Mustang intends to combine an oncolytic virus with an interleukin-13 Rα2-(IL13Rα2)-specific chimeric antigen receptor to potentially enhance efficacy in treating glioblastoma multiforme.
Teva will apply Insilico’s technology for predictive biomanufacturing to create more efficient biomanufacturing processes.